Duke, AIS Announce Collaboration To Build Cell Processing Center

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 8
Volume 4
Issue 8

DURHAM, NC--Duke University Medical Center and ExVivo Therapies have announced a collaboration to construct and operate a cell processing center, the first on the East Coast. ExVivo is a joint venture between Applied Immune Sciences (AIS) and Rhône-Poulenc Rorer.

DURHAM, NC--Duke University Medical Center and ExVivo Therapieshave announced a collaboration to construct and operate a cellprocessing center, the first on the East Coast. ExVivo is a jointventure between Applied Immune Sciences (AIS) and Rhône-PoulencRorer.

The Durham center, due for completion in late 1995, will processcells to be used in clinical trials of cell and gene therapiesfor certain forms of cancer, AIDS, and other diseases.

Articles in this issue
Physicians Take Aim at Localized Prostate Cancer Treatment Controversy in 'Shootout'
CA 125 Predicts Response to Chemo in Ovarian Ca
Biochemical Modulation Promising in RT-Resistant GI Cancer
Cancer Institute of NJ Adds to its Staff
A Century of Breast Cancer Litigation Is 'Deconstructed'
New Depot Formulation of LHRH Analogue Allows 12-Week Dosing
NSABP Investigation Threatens Academic Freedom for All: Fisher
Cancer Fax Directory in 3rd Edition
HIV-Related Malignancies Increasing, Physicians Tell Panel
Breast Cancer Risk Factors Remain Elusive Target
Conference Celebrates 100 Years of Radiology
Coalition Promotes Worksite Cancer Screening
Search for Ovarian Cancer Screen Must Look Beyond Ultrasound
DNA Defects Predict Endometrial Ca Prognosis
Cost Studies Help Determine Best BMT Use
Recent Videos
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
9 Experts are featured in this series.
9 Experts are featured in this series.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
2 experts are featured in this series.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
9 Experts are featured in this series.
Related Content
The updated labeling also includes new information on the recommended dosage of fludarabine phosphate when given with cyclophosphamide and rituximab.

FDA Updates Fludarabine Phosphate Labeling in Chronic Lymphocytic Leukemia

Russ Conroy
November 21st 2024
Article

The updated labeling also includes new information on the recommended dosage of fludarabine phosphate when given with cyclophosphamide and rituximab.

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

Collaboration Fosters Treatment Advancements for Young Lymphoma Populations

Andrew M. Evens, DO, MS
November 18th 2024
Podcast

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

Multiple Myeloma Experts Face Off on Sequencing Therapy Options

Multiple Myeloma Experts Face Off on Sequencing Therapy Options

ONCOLOGY Staff
November 21st 2024
Article

Experts in multiple myeloma gathered to debate current treatment options in the space during a recent Face Off.

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

Educating Patients and Clinicians on End-of-Life Care and Discussions

Kelley A. Rone, DNP, RN, AGNP-c
November 11th 2024
Podcast

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

Results from the TRIDENT-1 and CARE trials, which showcased durable activity and robust responses with repotrectinib, supported the recommendation.

EU Approval Recommended for Repotrectinib in ROS1+ NSCLC, NTRK+ Solid Tumors

Roman Fabbricatore
November 20th 2024
Article

Results from the TRIDENT-1 and CARE trials, which showcased durable activity and robust responses with repotrectinib, supported the recommendation.

For patients with NSCLC, subcutaneous pembrolizumab appeared noninferior vs intravenous pembrolizumab for study end points when combined with chemotherapy.

Subcutaneous Pembrolizumab/Chemo Meets Pharmacokinetic Endpoints in NSCLC

Tim Cortese
November 20th 2024
Article

For patients with NSCLC, subcutaneous pembrolizumab appeared noninferior vs intravenous pembrolizumab for study end points when combined with chemotherapy.